Psychiatric disorders have emerged as significant contributors to the global burden of disease in recent decades.The endocannabinoid system(ECS)influences a range of physiological and pathophysiological processes,incl...Psychiatric disorders have emerged as significant contributors to the global burden of disease in recent decades.The endocannabinoid system(ECS)influences a range of physiological and pathophysiological processes,including nociception,cognition,appetite,memory,and behavior,serving as a crucial mediator in psychiatric disorders.Imaging the ECS provides valuable insights into the pathophysiological mechanisms underlying psychiatric disorders and enhances clinical management strategies.As an advanced noninvasive molecular imaging modality,positron emission tomography(PET)enables the in vivo exploration of biological processes at the cellular and molecular levels.Recent advancements have led to the development of numerous PET tracers that target various components of the ECS,offering opportunities to visualize,characterize,and quantify ECS activity in psychiatric disorders in vivo.In this review,we summarize the existing PET tracers for ECS imaging and discuss their applications in diverse psychiatric conditions,including cannabis use disorder,alcohol use disorder,post-traumatic stress disorder,schizophrenia,and eating disorders.展开更多
Background:Vascular thrombus is a common complication in cancer patients and can be classified as benign or neoplastic based on tumor cell presence.Conventional imaging modalities provide anatomical information but ex...Background:Vascular thrombus is a common complication in cancer patients and can be classified as benign or neoplastic based on tumor cell presence.Conventional imaging modalities provide anatomical information but exhibit limited specificity in distinguishing neoplastic from benign thrombi,prompting the evaluation of 2‐deoxy‐2‐[^(18)F]fluoro‐D‐glucose positron emission tomography/computed tomography([^(18)F]FDG PET/CT),which leverages metabolic differences for improved differentiation.In this study,the efficacy of[^(18)F]FDG PET/CT for differentiating neoplastic thrombus from benign thrombus was evaluated in patients with malignant tumors.Methods:Sixty‐five patients with histologically or clinically confirmed neoplastic or benign thrombus who underwent[^(18)F]FDG PET/CT were retrospectively enrolled.Both visual and semi‐quantitative analyses of the PET/CT scans were conducted.The difference in maximum standardized uptake value(SUVmax)between neoplastic and benign thrombus was assessed using a t‐test.Furthermore,receiver operating characteristics(ROC)analysis was performed to determine the optimal SUVmax threshold for differentiating neoplastic from benign thrombus.Results:Within the cohort,55 patients were diagnosed with neoplastic thrombus and 10 patients with benign thrombus.In the visual analysis,the sensitivity,specificity,positive predictive value,negative predictive value,and diagnostic accuracy of[^(18)F]FDG PET/CT for diagnosing neoplastic thrombus were 96.4%,90.0%,98.1%,81.8%,and 95.4%,respectively.In the semiquantitative analysis,the sensitivity,specificity,positive predictive value,negative predictive value,and diagnostic accuracy for diagnosing neoplastic thrombus were 96.4%,100%,100%,83.3%,and 96.9%,respectively.The normalized SUVmax of neoplastic thrombus was significantly higher than that of benign thrombus(10.11�5.32 vs.2.21�0.51,p<0.001).The area under the ROC curves for visual assessment and semi‐quantitative analysis were 0.932 and 0.993,respectively.There was no statistically significant difference observed between these two assessment methods(p=0.317).Conclusions:[^(18)F]FDG PET/CT is capable of differentiating neoplastic thrombus from benign thrombus.Both visual and semiquantitative analyses demonstrated high diagnostic sensitivity,specificity,and accuracy.展开更多
基金supported by the National Key Research and Development Program of China(2022YFE0118000,2021YFA1101700)the National Natural Science Foundation of China(82030049,32027802,82394433,82361148130,and 82302262)+2 种基金the Zhejiang Provincial Natural Science Foundation(LMS25H180002)the Postdoctoral Fellowship Program of CPSF(GZC20251313)the Fundamental Research Funds for the Central Universities of China(226-2024-00059).
文摘Psychiatric disorders have emerged as significant contributors to the global burden of disease in recent decades.The endocannabinoid system(ECS)influences a range of physiological and pathophysiological processes,including nociception,cognition,appetite,memory,and behavior,serving as a crucial mediator in psychiatric disorders.Imaging the ECS provides valuable insights into the pathophysiological mechanisms underlying psychiatric disorders and enhances clinical management strategies.As an advanced noninvasive molecular imaging modality,positron emission tomography(PET)enables the in vivo exploration of biological processes at the cellular and molecular levels.Recent advancements have led to the development of numerous PET tracers that target various components of the ECS,offering opportunities to visualize,characterize,and quantify ECS activity in psychiatric disorders in vivo.In this review,we summarize the existing PET tracers for ECS imaging and discuss their applications in diverse psychiatric conditions,including cannabis use disorder,alcohol use disorder,post-traumatic stress disorder,schizophrenia,and eating disorders.
基金supported by the National Natural Science Foundation of China(Grant 32027802)the Key R&D Program of Zhejiang(Grant 2022C03071)the Fundamental Research Funds for the Central Universities(Grant 226‐2024‐00059).
文摘Background:Vascular thrombus is a common complication in cancer patients and can be classified as benign or neoplastic based on tumor cell presence.Conventional imaging modalities provide anatomical information but exhibit limited specificity in distinguishing neoplastic from benign thrombi,prompting the evaluation of 2‐deoxy‐2‐[^(18)F]fluoro‐D‐glucose positron emission tomography/computed tomography([^(18)F]FDG PET/CT),which leverages metabolic differences for improved differentiation.In this study,the efficacy of[^(18)F]FDG PET/CT for differentiating neoplastic thrombus from benign thrombus was evaluated in patients with malignant tumors.Methods:Sixty‐five patients with histologically or clinically confirmed neoplastic or benign thrombus who underwent[^(18)F]FDG PET/CT were retrospectively enrolled.Both visual and semi‐quantitative analyses of the PET/CT scans were conducted.The difference in maximum standardized uptake value(SUVmax)between neoplastic and benign thrombus was assessed using a t‐test.Furthermore,receiver operating characteristics(ROC)analysis was performed to determine the optimal SUVmax threshold for differentiating neoplastic from benign thrombus.Results:Within the cohort,55 patients were diagnosed with neoplastic thrombus and 10 patients with benign thrombus.In the visual analysis,the sensitivity,specificity,positive predictive value,negative predictive value,and diagnostic accuracy of[^(18)F]FDG PET/CT for diagnosing neoplastic thrombus were 96.4%,90.0%,98.1%,81.8%,and 95.4%,respectively.In the semiquantitative analysis,the sensitivity,specificity,positive predictive value,negative predictive value,and diagnostic accuracy for diagnosing neoplastic thrombus were 96.4%,100%,100%,83.3%,and 96.9%,respectively.The normalized SUVmax of neoplastic thrombus was significantly higher than that of benign thrombus(10.11�5.32 vs.2.21�0.51,p<0.001).The area under the ROC curves for visual assessment and semi‐quantitative analysis were 0.932 and 0.993,respectively.There was no statistically significant difference observed between these two assessment methods(p=0.317).Conclusions:[^(18)F]FDG PET/CT is capable of differentiating neoplastic thrombus from benign thrombus.Both visual and semiquantitative analyses demonstrated high diagnostic sensitivity,specificity,and accuracy.
